These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15790200)

  • 1. New ways to prevent venous thromboembolism--the pentasaccharide fondaparinux and the thrombin inhibitor ximelagatran--a review.
    Bergqvist D
    Acta Chir Belg; 2005 Feb; 105(1):35-9. PubMed ID: 15790200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
    Andersen JC
    Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations.
    Rosencher N
    Anaesthesia; 2004 Aug; 59(8):803-10. PubMed ID: 15270973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New anticoagulants for treatment of venous thromboembolism.
    Weitz JI
    Circulation; 2004 Aug; 110(9 Suppl 1):I19-26. PubMed ID: 15339877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation.
    McCullough PA; Dorrell KA; Sandberg KR; Yerkey MW
    Rev Cardiovasc Med; 2004; 5(2):99-103. PubMed ID: 15184843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter 1: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Wille-Jorgensen P
    Br J Surg; 2006 Mar; 93(3):374; author reply 375-6. PubMed ID: 16498577
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter 3: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Agnelli G; Bergqvist D; Dahl O; Eriksson B; Rud Lassen M; Mouret P; Rosencher N
    Br J Surg; 2006 Mar; 93(3):375; author reply 375-6. PubMed ID: 16498579
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter 2: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Tangelder MJ; Bylock A; Held P
    Br J Surg; 2006 Mar; 93(3):374-5; author reply 375-6. PubMed ID: 16498578
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs].
    Falciani M; Imberti D; Prisco D
    Recenti Prog Med; 2005 Apr; 96(4):196-204. PubMed ID: 15932039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prophylaxis of postoperative thromboembolism. New alternatives to low-molecular-weight heparin].
    Bergqvist D; Siegbahn A
    Lakartidningen; 2002 Jul; 99(28-29):3039-41. PubMed ID: 12170516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The oral direct thrombin inhibitor Ximelagatran Prophylaxis of venous thromboembolism in hip and knee replacement].
    Mouret P
    Hamostaseologie; 2002 Aug; 22(3):21-4. PubMed ID: 12215757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials of new anticoagulants.
    Anderson J; O'Donnell M
    Vnitr Lek; 2006 Mar; 52 Suppl 1():123-6. PubMed ID: 16637460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New anticoagulants in clinical practice].
    Boda Z
    Orv Hetil; 2004 Dec; 145(49):2467-74. PubMed ID: 15633734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
    Eriksson H; Lundström T; Wåhlander K; Clason SB; Schulman S;
    Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two new antithrombotic agents (fondaparinux and ximelagatran) and their implications in anesthesia.
    de Moerloose P; Boehlen F
    Can J Anaesth; 2002; 49(6):S5-10. PubMed ID: 12557410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of fondaparinux for the prevention and treatment of venous thromboembolism.
    Turpie AG
    Expert Opin Drug Saf; 2005 Jul; 4(4):707-21. PubMed ID: 16011449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation.
    Hellgren M; Johansson S; Eriksson UG; Wåhlander K
    BJOG; 2005 May; 112(5):579-83. PubMed ID: 15842280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ximelagatran for secondary prevention of venous thromboembolism.
    Böger C; Schroll S; Holmer S
    N Engl J Med; 2004 Feb; 350(6):618-9; author reply 618-9. PubMed ID: 14768068
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.